Business Description
Generation Bio Co
NAICS : 541714
SIC : 2834
ISIN : US37148K1007
Share Class Description:
GBIO: Ordinary SharesDescription
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.97 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.9 | |||||
| Debt-to-EBITDA | -1.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -4.58 | |||||
| Beneish M-Score | 3.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 10.2 | |||||
| 3-Year EPS without NRI Growth Rate | 12.7 | |||||
| 3-Year FCF Growth Rate | 30.5 | |||||
| 3-Year Book Growth Rate | -19.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.88 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.4 | |||||
| 9-Day RSI | 21.34 | |||||
| 14-Day RSI | 25.86 | |||||
| 3-1 Month Momentum % | -29.62 | |||||
| 6-1 Month Momentum % | -46.49 | |||||
| 12-1 Month Momentum % | -9.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.34 | |||||
| Quick Ratio | 6.34 | |||||
| Cash Ratio | 6.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.7 | |||||
| Shareholder Yield % | -17.98 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -525.52 | |||||
| Net Margin % | -782.87 | |||||
| FCF Margin % | -561.62 | |||||
| ROE % | -92.44 | |||||
| ROA % | -46.74 | |||||
| ROIC % | -100.64 | |||||
| 3-Year ROIIC % | -56.11 | |||||
| ROC (Joel Greenblatt) % | -168.12 | |||||
| ROCE % | -35 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.11 | |||||
| PB Ratio | 0.74 | |||||
| Price-to-Tangible-Book | 0.74 | |||||
| EV-to-EBIT | 0.12 | |||||
| EV-to-EBITDA | 0.12 | |||||
| EV-to-Revenue | -0.62 | |||||
| EV-to-Forward-Revenue | 0.03 | |||||
| EV-to-FCF | 0.11 | |||||
| Price-to-Net-Current-Asset-Value | 1.66 | |||||
| Price-to-Net-Cash | 1.9 | |||||
| Earnings Yield (Greenblatt) % | 833.33 | |||||
| FCF Yield % | -134.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Generation Bio Co Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 18.582 | ||
| EPS (TTM) ($) | -2.19 | ||
| Beta | 2.25 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.24 | ||
| Volatility % | 103.98 | ||
| 14-Day RSI | 25.86 | ||
| 14-Day ATR ($) | 0.145925 | ||
| 20-Day SMA ($) | 1.3545 | ||
| 12-1 Month Momentum % | -9.85 | ||
| 52-Week Range ($) | 1.11 - 4.65 | ||
| Shares Outstanding (Mil) | 66.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Generation Bio Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Generation Bio Co Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Generation Bio Co Frequently Asked Questions
What is Generation Bio Co(GBIO)'s stock price today?
The current price of GBIO is $1.16. The 52 week high of GBIO is $4.65 and 52 week low is $1.11.
When is next earnings date of Generation Bio Co(GBIO)?
The next earnings date of Generation Bio Co(GBIO) is 2025-03-06 Est..
Does Generation Bio Co(GBIO) pay dividends? If so, how much?
Generation Bio Co(GBIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers